NASDAQ:FDMT | Free Cash Flow | 4D Molecular Therapeutics, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2019-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$68.13M
2025-12-31$28.55M-$70,000.00$28.48M146.83%
2025-03-31-$47.76M$631,000.00-$48.39M
2024-12-31-$45.86M$949,000.00-$46.81M
2024-03-31-$29.09M$710,000.00-$29.8M
2023-12-31-$24.65M$549,000.00-$25.2M
2023-03-31-$27.91M$1.01M-$28.92M
2022-12-31-$22.21M$1.09M-$23.31M
2022-03-31-$23.55M$6.41M-$29.96M
2021-12-31-$21.84M$5.1M-$26.93M
2021-03-31-$15.37M$642,000.00-$16.01M
2020-12-31-$17.5M$508,000.00-$18.01M
2020-03-31-$13.87M$721,000.00-$14.59M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$109.08M$536,000.00-$109.62M
2024-12-31-$134.59M$3.79M-$138.37M
2023-12-31-$75.79M$2.77M-$78.56M
2022-12-31-$86.69M$11.54M-$98.22M
2021-12-31-$69.13M$9.11M-$78.24M
2020-12-31-$50.91M$1M-$51.91M
2019-12-31-$36.71M$3.2M-$39.91M